Providence Health and Services: Immunotherapies for GI and Lung Cancers Evaluated in New Studies
November 21, 2023
November 21, 2023
RENTON, Washington, Nov. 21 (TNSres) -- Providence Health and Services issued the following news:
This month we're featuring three clinical trials open at multiple Providence Cancer Institute of Oregon sites. The first study is for people with locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma. The two studies that follow are for people with non-small cell lung cancer (NSCLC) - locally advanced, unresectable or metastatic NSCLC and . . .
This month we're featuring three clinical trials open at multiple Providence Cancer Institute of Oregon sites. The first study is for people with locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma. The two studies that follow are for people with non-small cell lung cancer (NSCLC) - locally advanced, unresectable or metastatic NSCLC and . . .